ArticleOncology letters2022
Primary malignant melanoma of the bladder collides with high-grade non-invasive urothelial papillary carcinoma: A case report.
Article in Oncology letters, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
- Urinary bladder collision tumors: A case report and literature review.Medicine internationalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study reported a case of primary malignant melanoma of the bladder colliding with high-grade non-invasive urothelial papillary carcinoma with clinical, pathologic and immunohistochemical analysis, and reviewed the relevant literature. A 74-year-old male presented with hematuria; B ultrasound and computed tomography revealed a solid mass in the bladder and transurethral resection of the bladder lesion was performed. Microscopically, the tumors were composed of morphologically diverse malignant melanomas (95%) and high-grade non-invasive urothelial papillary carcinoma (5%), with no closely related or transitional regions. Immunohistochemistry indicated that malignant melanoma cells expressed HMB45, Melan-A and S-100, whereas they did not express any epithelial markers. The urothelial carcinomas expressed broad-spectrum cytokeratin and GATA3, and were negative for melanoma markers. The diagnosis of collision tumor between primary malignant melanoma of bladder and high-grade non-invasive urothelial papillary carcinoma depends on clinical and pathological examinations; this pathology is prone to recurrence and metastasis and has a poor prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.